	US 11,986,488 B2
	Compositions and methods for treating malignant, autoimmune and inflammatory diseases
Idit Shachar, Ramat-Gan (IL); Hadas Lewinsky, Rehovot (IL); Lihi Radomir, Rehovot (IL); and Anna Wiener, Rehovot (IL)
Assigned to Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed on Nov. 5, 2020, as Appl. No. 17/089,769.
Application 17/089,769 is a division of application No. 16/068,172, granted, now 10,828,318, previously published as PCT/IL2017/050019, filed on Jan. 5, 2017.
Claims priority of provisional application 62/275,378, filed on Jan. 6, 2016.
Prior Publication US 2021/0052626 A1, Feb. 25, 2021
Int. Cl. A61K 31/713 (2006.01); A61K 38/17 (2006.01); A61P 29/00 (2006.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 31/713 (2013.01) [A61K 38/1774 (2013.01); A61P 29/00 (2018.01); A61P 35/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)]

9 Claims

1. A method of treating an autoimmune or inflammatory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide agent capable of hybridizing to a gene or mRNA encoding CD84 and decreasing expression of a CD84 polypeptide or an antibody capable of decreasing an activity of a CD84 polypeptide, thereby treating the autoimmune or inflammatory disease in the subject, with the proviso that said disease is not a B cell malignancy.